Cancer Biotech Adaptimmune Files $191M IPO
Venture capital-backed Adaptimmune Therapeutics PLC, led by Mayer Brown LLP, rumbled onto the market on Wednesday, raising $191.2 million through an initial public offering as the U.K.-based immunotherapy treatment developer joins...To view the full article, register now.
Already a subscriber? Click here to view full article